Cargando…
The prevalence of antibodies to SARS-CoV-2 among blood donors in China
In this study, we investigate the seroprevalence of SARS-CoV-2 antibodies among blood donors in the cities of Wuhan, Shenzhen, and Shijiazhuang in China. From January to April 2020, 38,144 healthy blood donors in the three cities were tested for total antibody against SARS-CoV-2 followed by pseudoty...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925561/ https://www.ncbi.nlm.nih.gov/pubmed/33654063 http://dx.doi.org/10.1038/s41467-021-21503-x |
| _version_ | 1783659295202607104 |
|---|---|
| author | Chang, Le Hou, Wangheng Zhao, Lei Zhang, Yali Wang, Yanbin Wu, Linfeng Xu, Tingting Wang, Lilin Wang, Juan Ma, Jian Wang, Lan Zhao, Junpeng Xu, Jing Dong, Juan Yan, Ying Yang, Ru Li, Yu Guo, Fei Cheng, Wenjuan Su, Yingying Zeng, Jinfeng Han, Wei Cheng, Tong Zhang, Jun Yuan, Quan Xia, Ningshao Wang, Lunan |
| author_facet | Chang, Le Hou, Wangheng Zhao, Lei Zhang, Yali Wang, Yanbin Wu, Linfeng Xu, Tingting Wang, Lilin Wang, Juan Ma, Jian Wang, Lan Zhao, Junpeng Xu, Jing Dong, Juan Yan, Ying Yang, Ru Li, Yu Guo, Fei Cheng, Wenjuan Su, Yingying Zeng, Jinfeng Han, Wei Cheng, Tong Zhang, Jun Yuan, Quan Xia, Ningshao Wang, Lunan |
| author_sort | Chang, Le |
| collection | PubMed |
| description | In this study, we investigate the seroprevalence of SARS-CoV-2 antibodies among blood donors in the cities of Wuhan, Shenzhen, and Shijiazhuang in China. From January to April 2020, 38,144 healthy blood donors in the three cities were tested for total antibody against SARS-CoV-2 followed by pseudotype SARS-CoV-2 neutralization tests, IgG, and IgM antibody testing. Finally, a total of 398 donors were confirmed positive. The age- and sex-standardized SARS-CoV-2 seroprevalence among 18–60 year-old adults (18–65 year-old in Shenzhen) was 2.66% (95% CI: 2.24%–3.07%) in Wuhan, 0.033% (95% CI: 0.0029%–0.267%) in Shenzhen, and 0.0028% (95% CI: 0.0001%–0.158%) in Shijiazhuang, respectively. Female sex and older-age were identified to be independent risk factors for SARS-CoV-2 seropositivity among blood donors in Wuhan. As most of the population of China remained uninfected during the early wave of the COVID-19 pandemic, effective public health measures are still certainly required to block viral spread before a vaccine is widely available. |
| format | Online Article Text |
| id | pubmed-7925561 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79255612021-03-21 The prevalence of antibodies to SARS-CoV-2 among blood donors in China Chang, Le Hou, Wangheng Zhao, Lei Zhang, Yali Wang, Yanbin Wu, Linfeng Xu, Tingting Wang, Lilin Wang, Juan Ma, Jian Wang, Lan Zhao, Junpeng Xu, Jing Dong, Juan Yan, Ying Yang, Ru Li, Yu Guo, Fei Cheng, Wenjuan Su, Yingying Zeng, Jinfeng Han, Wei Cheng, Tong Zhang, Jun Yuan, Quan Xia, Ningshao Wang, Lunan Nat Commun Article In this study, we investigate the seroprevalence of SARS-CoV-2 antibodies among blood donors in the cities of Wuhan, Shenzhen, and Shijiazhuang in China. From January to April 2020, 38,144 healthy blood donors in the three cities were tested for total antibody against SARS-CoV-2 followed by pseudotype SARS-CoV-2 neutralization tests, IgG, and IgM antibody testing. Finally, a total of 398 donors were confirmed positive. The age- and sex-standardized SARS-CoV-2 seroprevalence among 18–60 year-old adults (18–65 year-old in Shenzhen) was 2.66% (95% CI: 2.24%–3.07%) in Wuhan, 0.033% (95% CI: 0.0029%–0.267%) in Shenzhen, and 0.0028% (95% CI: 0.0001%–0.158%) in Shijiazhuang, respectively. Female sex and older-age were identified to be independent risk factors for SARS-CoV-2 seropositivity among blood donors in Wuhan. As most of the population of China remained uninfected during the early wave of the COVID-19 pandemic, effective public health measures are still certainly required to block viral spread before a vaccine is widely available. Nature Publishing Group UK 2021-03-02 /pmc/articles/PMC7925561/ /pubmed/33654063 http://dx.doi.org/10.1038/s41467-021-21503-x Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Article Chang, Le Hou, Wangheng Zhao, Lei Zhang, Yali Wang, Yanbin Wu, Linfeng Xu, Tingting Wang, Lilin Wang, Juan Ma, Jian Wang, Lan Zhao, Junpeng Xu, Jing Dong, Juan Yan, Ying Yang, Ru Li, Yu Guo, Fei Cheng, Wenjuan Su, Yingying Zeng, Jinfeng Han, Wei Cheng, Tong Zhang, Jun Yuan, Quan Xia, Ningshao Wang, Lunan The prevalence of antibodies to SARS-CoV-2 among blood donors in China |
| title | The prevalence of antibodies to SARS-CoV-2 among blood donors in China |
| title_full | The prevalence of antibodies to SARS-CoV-2 among blood donors in China |
| title_fullStr | The prevalence of antibodies to SARS-CoV-2 among blood donors in China |
| title_full_unstemmed | The prevalence of antibodies to SARS-CoV-2 among blood donors in China |
| title_short | The prevalence of antibodies to SARS-CoV-2 among blood donors in China |
| title_sort | prevalence of antibodies to sars-cov-2 among blood donors in china |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925561/ https://www.ncbi.nlm.nih.gov/pubmed/33654063 http://dx.doi.org/10.1038/s41467-021-21503-x |
| work_keys_str_mv | AT changle theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT houwangheng theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT zhaolei theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT zhangyali theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT wangyanbin theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT wulinfeng theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT xutingting theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT wanglilin theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT wangjuan theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT majian theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT wanglan theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT zhaojunpeng theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT xujing theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT dongjuan theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT yanying theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT yangru theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT liyu theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT guofei theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT chengwenjuan theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT suyingying theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT zengjinfeng theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT hanwei theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT chengtong theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT zhangjun theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT yuanquan theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT xianingshao theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT wanglunan theprevalenceofantibodiestosarscov2amongblooddonorsinchina AT changle prevalenceofantibodiestosarscov2amongblooddonorsinchina AT houwangheng prevalenceofantibodiestosarscov2amongblooddonorsinchina AT zhaolei prevalenceofantibodiestosarscov2amongblooddonorsinchina AT zhangyali prevalenceofantibodiestosarscov2amongblooddonorsinchina AT wangyanbin prevalenceofantibodiestosarscov2amongblooddonorsinchina AT wulinfeng prevalenceofantibodiestosarscov2amongblooddonorsinchina AT xutingting prevalenceofantibodiestosarscov2amongblooddonorsinchina AT wanglilin prevalenceofantibodiestosarscov2amongblooddonorsinchina AT wangjuan prevalenceofantibodiestosarscov2amongblooddonorsinchina AT majian prevalenceofantibodiestosarscov2amongblooddonorsinchina AT wanglan prevalenceofantibodiestosarscov2amongblooddonorsinchina AT zhaojunpeng prevalenceofantibodiestosarscov2amongblooddonorsinchina AT xujing prevalenceofantibodiestosarscov2amongblooddonorsinchina AT dongjuan prevalenceofantibodiestosarscov2amongblooddonorsinchina AT yanying prevalenceofantibodiestosarscov2amongblooddonorsinchina AT yangru prevalenceofantibodiestosarscov2amongblooddonorsinchina AT liyu prevalenceofantibodiestosarscov2amongblooddonorsinchina AT guofei prevalenceofantibodiestosarscov2amongblooddonorsinchina AT chengwenjuan prevalenceofantibodiestosarscov2amongblooddonorsinchina AT suyingying prevalenceofantibodiestosarscov2amongblooddonorsinchina AT zengjinfeng prevalenceofantibodiestosarscov2amongblooddonorsinchina AT hanwei prevalenceofantibodiestosarscov2amongblooddonorsinchina AT chengtong prevalenceofantibodiestosarscov2amongblooddonorsinchina AT zhangjun prevalenceofantibodiestosarscov2amongblooddonorsinchina AT yuanquan prevalenceofantibodiestosarscov2amongblooddonorsinchina AT xianingshao prevalenceofantibodiestosarscov2amongblooddonorsinchina AT wanglunan prevalenceofantibodiestosarscov2amongblooddonorsinchina |